se of Digital Health to improve care of hematopoietic cell transplantation survivors
Not Applicable
- Conditions
- Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismHealth Condition 2: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
- Registration Number
- CTRI/2021/08/035686
- Lead Sponsor
- American Society of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
(1) all adults (Age >= 18 years at the time of transplant), (2) all types of transplant (autologous/ allogeneic, irrespective of graft source or conditioning regimen), (3) survival 100 days after most recent HCT with no evidence of relapse, disease progression on the last follow-up, and (4) consent to be approachedusing the NDHM interface
Exclusion Criteria
Exclusion criteria will include (1) patients with non-availability of smart-phone based internet services, (2) evidence of disease relapse or progression
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) vaccination initiation at day+180 post HCT, (2) bone-health surveillance [DXA scan] and (3) cardio-metabolic surveillance at day+100 post HCT.Timepoint: [3-9 months after the study intervention]
- Secondary Outcome Measures
Name Time Method To determine (1) Healthcare resource utilization by one-year [scored based on the frequency of contact with a family practitioner, specialist or transplant team visit], (2) Change in HR-QoL at one-year using regional language validated Functional Assessment of Cancer Therapy - Bone Marrow Transplantation [FACT-BMT (12)]and Patient-Reported Outcomes Measurement Information System Global Health [PROMIS-GH(13)] questionnaires administered at scheduled in-person visit or telemedicine(14), (3) Document reasons for non-adherence (financial reasons, lack of time, poor understanding of test importance, non-availability of tests/ caregiver, not communicated by the clinician) and time delay (days) in adherence since the recommended time point, (4) Any intervention subsequent to recommended surveillance results (Anti-resorptive therapy, lipid-lowering agents, anti-hypertension drugs, drugs to control blood glucose, thyroid supplements, etc)Timepoint: [from baseline to 9 months after study intervention]